Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECALL-Pilot polypill feasibility study for prevention of cognitive impairment
ACTRN12623000555651Phase 4Completed
- Sponsor
- The George Institute for Global Health
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telmisartan + amlodipine + indapamide, telmisartan, amlodipine and indapamide in Mild Cognitive Impairment (MCI), Dementia, hypertension (HTN) and 1 more, sponsored by The George Institute for Global Health. Primary endpoint: Feasibility of recruitment. Started Apr 2024; status: completed.
02
Drugs
telmisartan + amlodipine + indapamidetelmisartanamlodipineindapamide
03
Conditions
Mild Cognitive Impairment (MCI)Dementiahypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on ACTRN12623000555651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000555651.